▲ 1.54%
prev close
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Congressional Trades
1
All tracked trades
Members Trading
1
Unique members
Net Activity
-1
0 buys · 1 sells
Members Who Traded This Stock
1 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2023-03-06 | BMRNBioMarin Pharmaceutical Inc. | Sell | $1,001 - $15,000 | 1143d ago | — |
2023-03-06
Daniel Goldman
BMRN
Amount
$1,001 - $15,000
Filed
1143d ago
Recent News
Powered by Polygon.io
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape
BioMarin Reveals Dwarfism Study Data, Stock Soars
CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally
Trade Timeline
Congressional activity, newest first
Daniel Goldman
2023-03-06 · Sale
$1,001 - $15,000